ArticleMedical oncology (Northwood, London, England)2025
UPP1/ARNT positive feedback loop drives gastric cancer progression through metabolism reprogramming.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- UPP1 in Cancer: Context-Dependent Roles in Metabolic Adaptation and Treatment Response.Current issues in molecular biology · 2026Review
- Cross-cohort multi-omics analysis identifies novel clusters driven by epithelial-mesenchymal transition signatures in gastric cancer.Cancer cell international · 2026Article
- Integrative Multiomics Analysis Reveals Tumor-Associated Macrophage Heterogeneity and a Prognostic Signature in Gastric Cancer.Human mutation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
UPP1 has been reported to be involved in the tumorigenesis of pancreatic ductal adenocarcinoma and lung adenocarcinoma. However, the role and mechanism of UPP1 in GC remain unclear. This study aims to reveal the biological function of UPP1 in GC and the mechanisms regulating GC progression. Analysis of public databases and clinical samples revealed that UPP1 was significantly upregulated in GC tissues and associated with poor prognosis. Functionally, UPP1 knockdown inhibited GC cell proliferation and migration in vitro and suppressed tumor growth in vivo. Mechanistically, UPP1 promoted metabolic reprogramming by activating hypoxia-related pathways and enhancing mitochondrial translation. UPP1/ARNT axis formed a positive feedback loop that upregulated the expression of key metabolic enzymes HK2, GLUT1, and LDHA. These upregulated enzymes modulated glycolytic and oxidative phosphorylation levels to influence cellular functions. Moreover, genetic inactivation of UPP1 sensitized tumors to metformin and doxycycline. In addition, UPP1 affected PD-L1 levels through NF-κB pathway, thereby influencing the tumor microenvironment of GC. Our findings reveal a novel role for UPP1 in linking metabolic reprogramming to immune evasion in GC. Targeting this pathway with doxycycline or metformin exploits this metabolic vulnerability and enhances anti-tumor immunity, which could be a promising strategy.
Indexed as
Identifiers
41284106What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.